CRISPR upped to outperform by Evercore on upcoming data
Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.
Wells Fargo initiates DENTSPLY with Equal Weight, $20 target
Wells Fargo (NYSE:WFC) began coverage on DENTSPLY SIRONA (NASDAQ: NASDAQ:XRAY) shares, assigning an Equal Weight rating and setting a price target of $20.00. The new rating comes as DENTSPLY SIRONA's ...
PG&E price target lowered to $15 from $20 at Evercore ISI
Evercore ISI analyst Michael Lonegan lowered the firm’s price target on PG&E to $15 from $20 and keeps an In Line rating on the shares. The ...
Evercore ISI Issues Positive Forecast for Confluent (NASDAQ:CFLT) Stock Price
Confluent (NASDAQ:CFLT – Get Free Report) had its target price upped by Evercore ISI from $32.00 to $40.00 in a report ...
Evercore ISI Remains a Buy on Ascendis Pharma (ASND)
In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with ...